Epstein Suzanne L, Kong Wing-pui, Misplon Julia A, Lo Chia-Yun, Tumpey Terrence M, Xu Ling, Nabel Gary J
Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Bethesda, MD 20852, USA.
Vaccine. 2005 Nov 16;23(46-47):5404-10. doi: 10.1016/j.vaccine.2005.04.047. Epub 2005 Jun 13.
Influenza epidemic and pandemic strains cannot be predicted with certainty. Current vaccines elicit antibodies effective against specific strains, but new strategies are urgently needed for protection against unexpected strains. DNA vaccines encoding conserved antigens protect animals against diverse subtypes, but their potency needs improvement. We tested DNA prime-recombinant adenoviral boost immunization to nucleoprotein (NP). Strong antibody and T cell responses were induced. Protection against challenge was T cell-dependent and substantially more potent than DNA vaccination alone. Importantly, vaccination protected against lethal challenge with highly pathogenic H5N1 virus. Thus, gene-based vaccination with NP may contribute to protective immunity against diverse influenza viruses through its ability to stimulate cellular immunity.
流感流行株和大流行株无法确切预测。目前的疫苗可诱导产生针对特定毒株的有效抗体,但迫切需要新的策略来预防意外出现的毒株。编码保守抗原的DNA疫苗可保护动物抵御多种亚型病毒,但它们的效力有待提高。我们测试了以核蛋白(NP)为靶点的DNA初免-重组腺病毒加强免疫方案。该方案诱导产生了强烈的抗体和T细胞应答。对攻毒的保护作用依赖于T细胞,且比单独使用DNA疫苗的效力显著更强。重要的是,该疫苗接种可抵御高致病性H5N1病毒的致死性攻毒。因此,基于基因的NP疫苗接种可能通过刺激细胞免疫的能力,为抵御多种流感病毒提供保护性免疫。